
According to Benzinga Pro data, during Q4, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $5.79 million. Earnings were up 28.51%, but Arcturus Therapeutics still reported an overall loss of $38.66 million. In Q3, Arcturus Therapeutics brought in $2.44 million in sales but lost $54.08 million in earnings.